---
title: "Safety Profile | Kisqali®"
description: "Review the safety profile of KISQALI + endocrine therapy, based on long-term data from MONALEESA and NATALEE trials."
canonical_url: "https://www.kisqali.com/advanced-breast-cancer/safety-data/safety-profile"
meta:
  "og:description": "Review the safety profile of KISQALI + endocrine therapy, based on long-term data from MONALEESA and NATALEE trials."
  "og:title": "Safety Profile"
---

## **Safety profile**

### **A well-established safety profile with KISQALI + ET \***<sup>(1–4)</sup>

**Real-world and diverse population studies confirm that KISQALI is well tolerated with a consistent safety profile in a broad range of HR+/HER2– ABC patients. **<sup>(2,3)</sup>

Any grade

Grade 3/4

Neutropenia<sup>†</sup>

Leukopenia

Anaemia

Nausea

Fatigue

Diarrhoea

Vomiting

Liver-related AEs

QTcF prolongation

**Percentage (%)**

0

10

20

30

40

50

60

70

80

\* Please consult your local Summary of Product Characteristics for the full KISQALI safety and tolerability profile.  
<sup>†</sup> Febrile neutropenia was reported in 1.7% of patients exposed to KISQALI in the phase III clinical studies. <sup>(1)</sup>

## Sitemap

See the full [sitemap](/sitemap.md) for all pages.